Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (Previously presented) A dispenser comprising an aerosol vial equipped with a dispensing valve, said aerosol vial containing a pharmaceutical aerosol formulation comprising particles of (a) formoterol or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof and (b) mometasone or a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof dispersed in a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof, and a bulking agent having a mass median diameter of less than one micron, and wherein an interior surface of the aerosol vial is coated with a fluorocarbon polymer.

2. (Original) A pharmaceutical aerosol formulation according to claim 1, wherein the formoterol is in the form of formoterol fumarate.

3. (Original) A pharmaceutical aerosol formulation according to claim 2, wherein the formoterol is in the form of formoterol fumarate dihydrate.

4. (Previously presented) A pharmaceutical aerosol formulation of claim 1, wherein the mometasone is in the form of mometasone furoate.

5. (Previously presented) A pharmaceutical aerosol formulation according to claim 1, wherein the formoterol is present in an amount of about 0.06 to 0.60 mg per ml.

6. (Previously presented) A pharmaceutical aerosol formulation according to claim 1, wherein the mometasone is present in amount of about 0.5 to 15.0 mg per ml.

7. (Previously presented) A pharmaceutical aerosol formulation according to claim 1, wherein the bulking agent is selected from groups consisting of ascorbic acid, saccharides, polysaccharides, amino acids, organic and inorganic salts, urea and propyliodone.

8. (Original) A pharmaceutical aerosol formulation according to claim 7, wherein the bulking agent is selected from lactose, DL-alanine, glucose, D-galactose, D(+)trehalose dihydrate, sucrose, maltose, D(+)raffinose pentahydrate, sodium saccharin, starches, modified celluloses, dextrins, dextrans, glycine, sodium chloride, calcium carbonate, sodium tartrate and calcium lactate.

9. (Previously presented) A pharmaceutical aerosol formulation according to claim 7, wherein the bulking agent is lactose.

10. (Previously presented) A pharmaceutical aerosol formulation according to claim 1, wherein the weight ratio of formoterol to bulking agent is in the range 1:0.1 to 1:30.

11. (Previously presented) A pharmaceutical aerosol formulation according to claim 1, wherein the bulking agent has a mass median diameter of not more than 300 nm.

12. (Previously presented) A pharmaceutical aerosol formulation according to claim 1, wherein the formulation further comprises a surfactant.

13. (Previously presented) A pharmaceutical aerosol formulation according to claim 1, wherein the formulation further comprises ethanol.

14. (Original) A pharmaceutical aerosol formulation according to claim 13, wherein ethanol is present in amount of from 0.1 to 5% by weight of the formulation.

15. (Cancelled)

16. (Cancelled)

17. (Original) A method of preparing a formulation according to claim 1, the method comprising the steps of (i) forming a slurry of bulking agent with a component of the formulation; (ii) subjecting the slurry to high pressure homogenization; and (iii) combining the resulting slurry with other components of the aerosol formulation.